Press

Back to Index

Kadmon Corporation Researchers Define Importance of ROCK2 Signaling Pathway in Human Autoimmune Response

– Data Published in Proceedings of the National Academy of Sciences –
– Results Suggest Role for ROCK2 Inhibition in Autoimmunity Treatment –

NEW YORK, November 10, 2014 – Kadmon Corporation, LLC, today announced the publication of data showing that ROCK2 (Rho-associated coiled-coiled kinase 2) plays a critical role in regulating immune response in humans, representing a new target for the treatment of autoimmune diseases. The publication appears online this week in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS).

A central goal in the study of autoimmune disease is to develop therapies that down-regulate autoaggressive immune responses while preserving the immune system’s ability to fight infections and tumors. The published data show how blocking the ROCK2 pathway with KD025, the Company’s orally bioavailable, potent and highly selective inhibitor of ROCK2, down-regulates the secretion of IL-21 and IL-17, two pro-inflammatory cytokines involved in the pathology of many autoimmune diseases. Selective inhibition of ROCK2 with KD025 also increases the suppressive function of regulatory T cells (Treg), helping to resolve inflammation, with a minimal effect on the rest of the immune response.

“This publication provides new insights into the role of the ROCK2 signaling pathway in regulating autoimmune response in humans,” said Alexandra Zanin-Zhorov, Ph.D., Senior Director of Immunology at Kadmon. “These data emphasize the therapeutic potential of selective ROCK2 inhibition in treating autoimmune diseases.”

“We have defined a crucial role for ROCK2 in immune cell function, and have shown that selective ROCK2 inhibition by KD025 represents an important new approach to autoimmune therapy,” said Harlan W. Waksal, M.D., President and CEO of Kadmon. “As we continue to advance our KD025 Phase 2 clinical program, we are developing a suite of ROCK2-specific compounds to permit the optimal pairing of inhibitors with a variety of autoimmune, fibrosis and neurodegenerative indications.”

The publication will be available online this week at http://www.pnas.org/content/111/47/16814.full.pdf?sid=0d160323-7820-457b-adfd-592f0f412346

 

About Kadmon Corporation

Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in oncology, autoimmune and fibrotic diseases, monogenic diseases and metabolic disease. For more information, visit www.kadmon.com.

This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact Information
Ellen Tremaine
Investors
646.490.2989
ellen.tremaine@kadmon.com

David Pitts
Argot Partners
212.600.1902
david@argotpartners.com

Download